IPAROMLIMAB AND TUVONRALIMAB INJECTION

Clinical trials for IPAROMLIMAB AND TUVONRALIMAB INJECTION explained in plain language.

Never miss a new study

Get alerted when new IPAROMLIMAB AND TUVONRALIMAB INJECTION trials appear

Sign up with your email to follow new studies for IPAROMLIMAB AND TUVONRALIMAB INJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1

New drug combo aims to stop liver cancer recurrence before surgery

Disease control Not yet recruiting

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in people with early-stage disease at high risk of recurrence. About 30 adults aged 18-75 with resectable stage IB o…

Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated May 17, 2026 02:02 UTC

IPAROMLIMAB AND TUVONRALIMAB INJECTION

Get alerted when new IPAROMLIMAB AND TUVONRALIMAB INJECTION trials appear

New drug combo aims to stop liver cancer recurrence before surgery